NCT03341013View on ClinicalTrials.gov

A Pilot Study Investigating Bioequivalence Between a Single Dose of Formulation 2 and Formulation 3 of MEDI0382

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

November 30, 2017

Primary Completion Date

January 29, 2018

Study Completion Date

January 29, 2018

Conditions
Type 2 Diabetes Mellitus
Interventions
DRUG

MEDI0382 Formulation 2

Sequence 1 Period 1 and Sequence 2 Period 2.

DRUG

MEDI0382 Formulation 3

Sequence 1 Period 2 and Sequence 2 Period 1

Trial Locations (1)

75247

Research Site, Dallas

Sponsors

Lead Sponsor

MedImmune LLC
All Listed Sponsors
lead

MedImmune LLC

INDUSTRY